Browsing Tag
H. Lundbeck A/S
3 posts
Two years in, is Lundbeck’s bexicaserin redefining how we treat drug-resistant seizures?
Lundbeck’s bexicaserin shows two-year seizure control in rare epilepsies. Explore how the durable data could redefine drug development in childhood DEEs.
Vyepti and Rexulti power Lundbeck (CPH: LUN) to raise 2025 guidance after 22% adjusted EBITDA surge
Lundbeck lifts 2025 guidance as Vyepti and Rexulti drive 22% EBITDA growth. Explore the neuroscience-focused strategy powering its latest earnings surge.
Vyepti by H. Lundbeck A/S shows robust Phase IV efficacy in chronic migraine with medication-overuse headache patients
H. Lundbeck A/S reports rapid and significant migraine prevention benefits for Vyepti® (eptinezumab) in Phase IV RESOLUTION trial, targeting MOH patients.